Fig. 3

Protein expression and drug sensitivity for associated protein inhibitors. A Immunohistochemistry of indicated proteins for initial tumor (YMG25P, left) and recurrent tumor (YMG25R, right). Bars, 50 µm. B Bar graphs indicating % positive stained cells for indicated proteins. C, D Relative cell viability following PDGFR inhibitor (C) and CDK4/6 inhibitor (D) treatment at day3. DMSO, control. *P < 0.05. Data are represented as the mean ± SEM